BTIG Research's Rating of Cullinan Therapeutics on 5/4/2026

On May 4, 2026, BTIG Research updated its outlook on Cullinan Therapeutics (NASDAQ:CGEM) with the action "Reiterated Rating", keeping a "Buy" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from BTIG Research

DateCompanyAction
11/20/2026
Ross Stores, Inc. stock logo
ROST
Ross Stores
Reiterated Rating
11/20/2026
Carpenter Technology Corporation stock logo
CRS
Carpenter Technology
Reiterated Rating
11/20/2026
BILL Holdings, Inc. stock logo
BILL
BILL
Downgrade
11/20/2026
Walmart Inc. stock logo
WMT
Walmart
Reiterated Rating
11/20/2026
The Gap, Inc. stock logo
GAP
GAP
Lower Price Target
11/19/2026
MongoDB, Inc. stock logo
MDB
MongoDB
Reiterated Rating
More Ratings From BTIG Research